research Safety and efficacy of ALRV5XR in men with androgenetic alopecia: A randomised, double-blinded, placebo-controlled clinical trial
ALRV5XR effectively increases hair density in men with androgenetic alopecia without adverse effects.
Search
for
Sort by
Research
150-180 / 1000+ resultsresearch Faculty Opinions recommendation of Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial.
DHEA therapy improved pubic hair growth and psychological well-being in young females with adrenal insufficiency.
research Faculty Opinions recommendation of Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device-controlled multicenter trial.
Low-level light therapy significantly increased hair density and thickness in people with hair loss, but they didn't notice a difference.
research 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
research Recovery Effects of Oral Supplementation with Polar Lipid-Rich Wheat Extracts on Acute Telogen Effluvium: A Randomized Double-Blind Placebo-Controlled Study
Wheat extract supplements reduce hair shedding and improve growth in women with hair loss.
research Topical Cyperus rotundus essential oil for treatment of axillary hyperpigmentation: a randomized, double‐blind, active‐ and placebo‐controlled study
Cyperus rotundus essential oil effectively treats underarm darkening, reduces inflammation, and slows hair growth.
research Low-Molecular-Weight Collagen Peptides Improve Hair Health in Adults with Damaged Hair: A Randomized, Double-Blind, Placebo-Controlled Trial
Collagen supplements improve hair health and are safe.
research Efficacy and Safety of a Low-level Laser Device in the Treatment of Male and Female Pattern Hair Loss: A Multicenter, Randomized, Sham Device-controlled, Double-blind Study
Laser device increases hair density, safe for treating hair loss in men and women.
research A randomized, double-blind controlled clinical study to evaluate the efficacy and safety of minoxidil topical 2% nanosuspension with aqueous base in the treatment of androgenetic alopecia areata
The 2% minoxidil nanosuspension is as effective as the commercial product but safer and easier to use.
research FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial
The trial aims to test if spironolactone is an effective acne treatment for women without the side effects of current treatments.
research The Role of Sesbania grandiflora-Derived Biotin and Bambusa arundinacea-Derived Silica Extracts in Promoting Hair, Skin, and Nail Health: A Randomized, Double-Blind, Placebo-Controlled Clinical Study
Biotin and silica from plants improve hair, skin, and nail health.
research A Study on the Effectiveness and Safety of Herbal Extract Combination Compared to 3% Minoxidil Solution for the Treatment of Androgenetic Alopecia: A Randomized, Double-blind, Controlled Trial
The herbal extract is as effective and safe as 3% minoxidil for treating hair loss.
research Scalp application of the antioxidant piroctone olamine reduces hair shedding in an 8‐week randomized, double‐blind, placebo‐controlled clinical study
Using piroctone olamine on the scalp helps reduce hair loss and improves scalp health.
research Efficacy, Safety, and Tolerability of a Wearable Electrotrichogenic Device in Men with Androgenetic Alopecia: A Randomized, Double-Blind, Sham-Controlled Trial
The device improved hair growth and thickness in men without side effects.
research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
CG2001 is safe and well-tolerated for treating hair loss, with fewer side effects than oral finasteride.
research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
CG2001 is safe, well-tolerated, and a promising treatment for hair loss with fewer side effects.
research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
CG2001 is safe and well-tolerated for treating hair loss in men.
research EFFICACY AND SAFETY OF STANDARDIZED CINNAMON BARK EXTRACT FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED WEIGHT LOSS AND ALOPECIA IN PATIENTS WITH BREAST CANCER: A RANDOMIZED, DOUBLE-BLIND, AND PLACEBO-CONTROLLED STUDY
Cinnamon bark extract may help prevent weight loss and hair loss in breast cancer patients during chemotherapy and is safe to use.
research A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial
SIM01 significantly reduced post-COVID symptoms and is safe.
research 5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men
5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.
research Platelet-Rich Plasma for Urologic Conditions: An Early Call for Composition Reporting
The conclusion is that future trials should report specific details about the PRP composition to better understand its effects on urologic conditions.
research Evaluation of Patellar Tendon Structural Changes following Biological Treatments: Secondary Analysis of Double-Blinded Clinical Trial of Bone Marrow Mesenchymal Stromal Cells and Leukocyte-Poor Platelet-Rich Plasma
Bone marrow cells improved tendon health better than platelet-rich plasma.
research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
research Efficacy and tolerability of HDMHG0401-10 in Patients with Androgenetic Alopecia: A Randomized Double-blind Placebo-controlled Trial
HDMHG0401-10 treatment significantly improved hair count and was better than a placebo in reducing hair loss in men with hereditary hair loss, with no major side effects.
research Efficacy of Botulinum Toxin in Male Androgenetic Alopecia: a Triple-Blind, Randomized Clinical Trial
Botulinum toxin may help treat male pattern baldness.
research Silymarin in combination with hair follicle transplantation as a potential treatment for refractory vitiligo: A double‐blind randomized controlled trial
Silymarin with hair follicle transplantation might help treat stubborn vitiligo, but more research is needed.
research Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.
research Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Efficacy and safety of topical 3% minoxidil for facial hair enhancement in transmen: a randomized, double-blind, placebo-controlled trial
Topical 3% minoxidil effectively and safely enhances facial hair in transgender men.